ATE178053T1 - N2s2-chelatoren des hydrazino-typs - Google Patents

N2s2-chelatoren des hydrazino-typs

Info

Publication number
ATE178053T1
ATE178053T1 AT94925320T AT94925320T ATE178053T1 AT E178053 T1 ATE178053 T1 AT E178053T1 AT 94925320 T AT94925320 T AT 94925320T AT 94925320 T AT94925320 T AT 94925320T AT E178053 T1 ATE178053 T1 AT E178053T1
Authority
AT
Austria
Prior art keywords
hydrazino
chelators
type
targetting molecules
conjugation
Prior art date
Application number
AT94925320T
Other languages
English (en)
Inventor
Alfred Pollak
Robert A Kirby
Robert Dufault
Original Assignee
Resolution Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22367562&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE178053(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Resolution Pharm Inc filed Critical Resolution Pharm Inc
Application granted granted Critical
Publication of ATE178053T1 publication Critical patent/ATE178053T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • C07C327/20Esters of monothiocarboxylic acids
    • C07C327/32Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/534Production of labelled immunochemicals with radioactive label
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Amplifiers (AREA)
  • Measurement Of Radiation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT94925320T 1993-09-03 1994-08-31 N2s2-chelatoren des hydrazino-typs ATE178053T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11650493A 1993-09-03 1993-09-03

Publications (1)

Publication Number Publication Date
ATE178053T1 true ATE178053T1 (de) 1999-04-15

Family

ID=22367562

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925320T ATE178053T1 (de) 1993-09-03 1994-08-31 N2s2-chelatoren des hydrazino-typs

Country Status (8)

Country Link
US (1) US5574140A (de)
EP (1) EP0716647B1 (de)
JP (1) JP3602848B2 (de)
AT (1) ATE178053T1 (de)
AU (1) AU7528894A (de)
CA (1) CA2169269A1 (de)
DE (1) DE69417426T2 (de)
WO (1) WO1995006633A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858327A (en) * 1993-09-03 1999-01-12 Resolutions Pharmaceuticals, Inc. Hydrazino-type N2 S2 radionuclide chelating compounds
US5804158A (en) * 1995-05-31 1998-09-08 Resolution Pharmaceuticals Inc. Sequestered imaging agents
DE19536783A1 (de) * 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope
WO1998033809A1 (en) * 1997-01-31 1998-08-06 The General Hospital Corporation Compositions and methods for imaging gene expression
US7060251B1 (en) 1997-09-08 2006-06-13 The General Hospital Corporation Imaging agents for early detection and monitoring of cardiovascular plaque
WO1999012579A1 (en) * 1997-09-08 1999-03-18 The General Hospital Corporation Imaging agents for early detection and monitoring of cardiovascular plaque
US6409987B1 (en) 1999-04-07 2002-06-25 Intimax Corporation Targeted agents useful for diagnostic and therapeutic applications
US6907280B2 (en) * 1999-12-02 2005-06-14 The General Hospital Corporation Method and apparatus for objectively measuring pain, pain treatment and other related techniques
WO2001039664A1 (en) * 1999-12-02 2001-06-07 The General Hospital Corporation Method and apparatus for measuring indices of brain activity
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
ES2398393T3 (es) 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
CN101558081B (zh) 2006-12-11 2014-08-20 伯拉考成像股份公司 用于诊断和治疗应用的纤维蛋白结合肽缀合体
EP2147684A1 (de) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Selektiv gegen Metallproteasen wirkende Diagnosemittel
US20150344523A1 (en) 2014-05-05 2015-12-03 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
EP3322716B1 (de) 2015-07-15 2025-02-12 California Institute of Technology Il-17f-spezifische einfänger und verfahren zur verwendung
WO2017137477A1 (en) 2016-02-09 2017-08-17 Bracco Suisse Sa A recombinant chimeric protein for selectins targeting
EP3440101B1 (de) 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-spezifische einfänger, zusammensetzungen und verfahren zur verwendung und herstellung davon
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
EP3535278A4 (de) 2016-11-01 2020-06-24 Ohio State Innovation Foundation Verfahren zur jodierung von biomolekülen
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
WO2020097531A1 (en) 2018-11-08 2020-05-14 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
CA3227425A1 (en) 2021-07-26 2023-02-02 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184571A (ja) * 1984-03-01 1985-09-20 Miyoshi Kasei:Kk 水素添加レシチンにより表面処理した化粧料用顔料
US4980147A (en) * 1984-06-25 1990-12-25 University Of Utah Research Foundation Radiolabeled technetium chelates for use in renal function determinations
US5120526A (en) * 1985-01-14 1992-06-09 Neorx Corporation Method of producing metal radionuclide labeled proteins for diagnosis and therapy
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5037630A (en) * 1985-01-14 1991-08-06 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5175343A (en) * 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
JPS63113081A (ja) * 1985-07-29 1988-05-18 Shiseido Co Ltd 改質粉体
ATE52516T1 (de) * 1986-05-28 1990-05-15 Mallinckrodt Inc Technetiumchelate fuer die bestimmung der nierenfunktion.
US5187264A (en) * 1986-05-28 1993-02-16 Mallinckrodt Medical, Inc. Technetium chelates to be used for determining the renal function
US4861869A (en) * 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US5082930A (en) * 1986-05-29 1992-01-21 Mallinckrodt Medical, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US4965392A (en) * 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
US5091514A (en) * 1987-03-26 1992-02-25 Neorx Corporation Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy
DE68923274T2 (de) * 1988-02-09 1995-11-09 Mallinckrodt Inc Verfahren zur herstellung eines mit metall-radionuklid-markierten proteins.
US5202451A (en) * 1988-02-17 1993-04-13 Neorx Corporation Anchimeric radiometal chelating compounds
JPH01224309A (ja) * 1988-03-03 1989-09-07 Pola Chem Ind Inc 化粧料
US5089249A (en) * 1988-06-10 1992-02-18 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US5196515A (en) * 1989-03-17 1993-03-23 The Johns Hopkins University Thiolactone bifunctional chelating agents for diagnostic and therapeutic products
JP2801639B2 (ja) * 1989-05-11 1998-09-21 株式会社三光生物科学研究所 メイクアップ用皮膚化粧料組成物
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5112953A (en) * 1989-12-29 1992-05-12 Neorx Corporation Radiolabeled proteins for diagnostic or therapeutic use
US5175257A (en) * 1989-12-29 1992-12-29 Neorx Corporation Radiolabeled proteins for diagnostic or therapeutic use
WO1991016076A1 (en) * 1990-04-17 1991-10-31 Mallinckrodt Medical, Inc. Method and kit for preparing technetium-99m complexes
JP2978989B2 (ja) * 1990-12-04 1999-11-15 エンジェルハード・コーポレイション 改良板状顔料
AU9172191A (en) * 1990-12-12 1992-07-08 Mallinckrodt Medical, Inc. Method of radioactive labelling of blood cells and kit therefor
US5908931A (en) * 1990-12-14 1999-06-01 Mallinckrodt Inc. Preorganized hexadentate ligands useful in radiographic imaging agents
US5243073A (en) * 1990-12-14 1993-09-07 Mallinckrodt Medical, Inc. Hexadentate ligands useful in radiographic imaging agents
US5112595A (en) * 1990-12-21 1992-05-12 Mallinckrodt Medical, Inc. 99MTC(III) myocardial imaging agents and method of use
US5112594A (en) * 1991-04-04 1992-05-12 Mallinckrodt Medical, Inc. Kit for preparing a technetium-99m myocardial imaging agent
AU1995392A (en) * 1991-05-08 1992-12-21 Mallinckrodt Medical, Inc. Technetium chelates to be used for determining the renal function
WO1992021383A1 (en) * 1991-06-03 1992-12-10 Mallinckrodt Medical, Inc. Radiolabelled somatostatin derivatives, their preparation and use
AU670029B2 (en) * 1991-08-05 1996-07-04 Mallinckrodt Medical, Inc. Heavy metal clusters for use as imaging agents

Also Published As

Publication number Publication date
WO1995006633A1 (en) 1995-03-09
EP0716647B1 (de) 1999-03-24
AU7528894A (en) 1995-03-22
CA2169269A1 (en) 1995-03-09
DE69417426T2 (de) 1999-10-28
JPH09503496A (ja) 1997-04-08
EP0716647A1 (de) 1996-06-19
DE69417426D1 (de) 1999-04-29
JP3602848B2 (ja) 2004-12-15
US5574140A (en) 1996-11-12

Similar Documents

Publication Publication Date Title
ATE178053T1 (de) N2s2-chelatoren des hydrazino-typs
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
DE69434384D1 (de) Metalkomplexbildner
ATE58297T1 (de) Kupplungsmittel zum radiomarkieren von proteinen.
NO301829B1 (no) 2-pyridylmetylenpolyazamakrocyklo-fosfonsyrer, komplekser og farmasöytiske preparater basert på disse
YU61701A (sh) Postupak i kit za efikasno radioobeležavanje proteina sa terapeutskim radioizotopom
ATE194845T1 (de) Von peptiden abgeleitete komplexbildner für radionuklide
DK0570493T3 (da) Technetium-99m-mærkede polypeptider til billeddannelse.
NO304552B1 (no) Kompleksforbindelser, konjugater, farmas°ytiske preparater inneholdende slike og forbindelser
ATE249845T1 (de) Strahlenschutzsubstanz fur radioisotopen markierte peptiden
EP0724456A4 (de) Antikörper gegen cd40
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
EP0350846A3 (en) Condensed heterocyclic compounds and their use in therapy
EP0765172A4 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ATE160222T1 (de) Photoaktivierung von proteinen zu konjugationszwecken
FI943724A0 (fi) Stabiloidut radiofarmaseuttiset pakkaukset
PT98193A (pt) Estojo para a dosagem especifica de angiotensina ii
ATE220688T1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
DE69230798D1 (de) Rekombinante immuntoxine
DE69127334D1 (de) Verabreichung von Mitteln
NO953865L (no) Bifunksjonelle chelatorer og deres anvendelse i radiofarmasöytiske midler
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
EP0659764A3 (de) Peptide modifiziert durch eine Phosphin Gruppe zur Markierung mit 99mTC und 186-188Re oder paramagnetische Agentien.
DE69117741D1 (de) Neue vorangeordnete sechszähnige liganden verwendbar in röntgenologischen bildformenden wirkstoffen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee